Niemann-Pick Disease Type C

Sponsored diagnostic testing programs for Niemann-Pick Disease Type C

Niemann-Pick disease type C is a lipid trafficking disorder leading to progressive neurologic decline, ataxia, vertical gaze palsy, cognitive impairment, and sometimes neonatal cholestasis or organomegaly. Age at onset is variable. Genetic testing confirms the diagnosis and supports treatment decisions, surveillance, and counseling.

3 programs found for Niemann-Pick Disease Type C

Programs

3 programs
Invitae Unlock™

Invitae Epilepsy Panel

This program provides access to genetic testing for pediatric patients under 18 who present with an unprovoked seizure. The panel evaluates key epilepsy-associated genes to support diagnostic confirmation, inform prognosis, and guide clinical management. Testing is available to eligible patients when ordered by a licensed healthcare provider.

Neurology

Invitae® Detect LSDs

Sponsored by
Passage Bio
Neurogene Inc.

Invitae Comprehensive Lysosomal Storage Disorders Panel

The Detect Lysosomal Storage Diseases Program provides no-charge genetic testing for patients in the US or Canada when an LSD is suspected. Eligible patients may present with clinical features, abnormal enzyme studies, positive newborn screens, or relevant family history. Testing through Invitae’s LSD panel can help confirm diagnosis and guide management.

Metabolic

The Lantern Project

Sponsored by
Sanofi

Lysosomal Disorders Testing Pathway

The Lantern Project provides sponsored genetic testing for patients with suspected lysosomal storage diseases (LSDs). LSDs are multisystem disorders caused by impaired lysosomal function and often present with overlapping features. This program supports timely diagnosis by offering testing options for major conditions including Gaucher, Fabry, Pompe, and multiple MPS subtypes.

Metabolic